Suppr超能文献

增殖活性(MIB-1指数)是除恶性纤维组织细胞瘤外其他亚型的高级别软组织肉瘤患者的独立预后参数:一项纳入216例软组织肉瘤的回顾性免疫组织学研究。

Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas.

作者信息

Jensen V, Sørensen F B, Bentzen S M, Ladekarl M, Nielsen O S, Keller J, Jensen O M

机构信息

Centre for Bone and Soft Tissue Sarcomas, University Hospital of Aarhus, Denmark.

出版信息

Histopathology. 1998 Jun;32(6):536-46.

PMID:9675593
Abstract

AIMS

To evaluate the prognostic value of tumour proliferative activity, p53 accumulation and bcl-2 expression in a retrospective series of 216 patients with soft tissue sarcomas (STS).

METHODS AND RESULTS

The immunohistochemical analyses were performed on formalin-fixed, paraffin-embedded tissue. The proliferative activity was assessed by use of the monoclonal antibody MIB-1 and evaluated in multiple, random systematic sampled fields of vision. The percentage of proliferating cells (the MIB-1 index) ranged between 1% and 85% (median 12%). A significant increase in mean MIB-1 index was seen with increasing histological malignancy grade. Variation in the incidence of p53 accumulation and bcl-2 positivity among different histological subtypes was observed. p53 accumulation was frequent in synovial sarcomas and leiomyo- and rhabdomyosarcomas, whereas bcl-2 preferentially was expressed in synovial sarcomas. Univariate analysis identified patient age, tumour size, histological grade of malignancy, MIB-1 index and p53 accumulation as significant prognostic parameters. Multivariate Cox analysis, including tests for interaction terms between histological subtypes and MIB-1 index, showed independent prognostic effect of MIB-1 index and tumour size in patients with high-grade tumours of other subtypes than malignant fibrous histiocytoma (MFH).

CONCLUSIONS

Histopathological malignancy grading is the most important single prognostic factor for overall survival in STS, but estimation of MIB-1 index is useful for identifying the least favourable subgroup of high grade STS of other subtypes than MFH, for whom adjuvant therapy may be indicated.

摘要

目的

在一项对216例软组织肉瘤(STS)患者的回顾性研究中,评估肿瘤增殖活性、p53蛋白积聚及bcl-2表达的预后价值。

方法与结果

对福尔马林固定、石蜡包埋的组织进行免疫组化分析。使用单克隆抗体MIB-1评估增殖活性,并在多个随机系统取样视野中进行评估。增殖细胞百分比(MIB-1指数)在1%至85%之间(中位数为12%)。随着组织学恶性程度分级增加,平均MIB-1指数显著升高。观察到不同组织学亚型之间p53蛋白积聚和bcl-2阳性发生率存在差异。p53蛋白积聚在滑膜肉瘤、平滑肌肉瘤和横纹肌肉瘤中常见,而bcl-2则优先在滑膜肉瘤中表达。单因素分析确定患者年龄、肿瘤大小、组织学恶性程度分级、MIB-1指数和p53蛋白积聚为显著的预后参数。多因素Cox分析,包括对组织学亚型与MIB-1指数之间交互项的检验,显示在除恶性纤维组织细胞瘤(MFH)以外的其他亚型的高级别肿瘤患者中,MIB-1指数和肿瘤大小具有独立的预后作用。

结论

组织病理学恶性程度分级是STS总体生存最重要的单一预后因素,但MIB-1指数评估对于识别除MFH以外的其他亚型高级别STS中最不利的亚组有用,对这些患者可能需要进行辅助治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验